ADA 2025 - Final results from the CATALYST trial show mifepristone significantly improved glucose control in patients with hypercortisolism and difficult-to-control diabetes.

We are joined by Dr John Buse (University of North Carolina, Chapel Hill, US) to discuss phase 4 results from CATALYST (NCT05772169), a randomised, placebo-controlled, multi-center trial investigating the safety and efficacy of mifepristone treatment of hypercortisolism in patients with difficult-to-control T2D.

Findings showed that patients who recieved mifepristone treatment had a clinically meaningful and statistically significant reduction in hemoglobin A1c, and had significantly reduced body weight and waist circumference compared to patients who received placebo.

Interview Questions:

1. What is the background behind the CATALYST trial?
2. What was the study design and patient population?
3. What were the key findings?
4. What are the take-home messages for practice?
5. What further research is needed in this area?

Recorded remotely from Chapel Hill, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographer: David Ben-Harosh

Support: This is an independent interview produced by Radcliffe CVRM.